Literature DB >> 31154933

The brief Dimensional Apathy Scale: A short clinical assessment of apathy.

Ratko Radakovic1,2,3,4, Sarah McGrory5, Siddharthan Chandran3, Robert Swingler3, Suvankar Pal3, Laura Stephenson3, Shuna Colville3, Judy Newton3, John M Starr2, Sharon Abrahams1,3.   

Abstract

Objective: Apathy is a prominent syndrome across neurodegenerative diseases. The Dimensional Apathy Scale (DAS) assesses three apathy subtypes-executive, emotional, and initiation-and is sensitive and valid in amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and Parkinson's disease. This study describes the development of the brief DAS (b-DAS), which will enable apathy to be swiftly detected in the clinic.Method: 102 ALS and 102 AD patients' previously collected data were used. Mokken analyses were performed on item-level data of each informant/carer-rated DAS subscale (executive, emotional, and initiation) for the initial scale reduction. Item-total correlational analyses against standard apathy (convergent validity criteria) and depression (divergent validity criteria) measures and qualitative examination of items aided final item selection. Receiver operating curve analysis determined optimal cutoffs for the reduced subscales.
Results: Mokken analyses suggested unidimensionality of each DAS subscale. Three items were removed that failed to satisfy monotone homogeneity model requirements, three items were removed due to validity criteria not being met, and six items were removed due to a combination of lower item scalability and item-total correlations. Item-theme examination further reduced the b-DAS to nine items, three per subscale, with a supplemental awareness deficit assessment being added. Sensitivity- and specificity-based optimal cutoffs were calculated for each b-DAS subscale.Conclusions: This study presents the b-DAS, an informant/carer-based robust yet short multidimensional apathy instrument with good convergent and divergent validity, with recommended clinical cutoffs. The b-DAS is appropriate for use in the clinic and for research to quickly and comprehensively screen for apathy subtype impairments.

Entities:  

Keywords:  Apathy; amyotrophic lateral sclerosis; assessment; dementia; short form

Mesh:

Year:  2019        PMID: 31154933     DOI: 10.1080/13854046.2019.1621382

Source DB:  PubMed          Journal:  Clin Neuropsychol        ISSN: 1385-4046            Impact factor:   3.535


  7 in total

1.  Developing and validating the Japanese version of Dimensional Apathy Scale (J-DAS).

Authors:  Toshikazu Kawagoe; Keiichi Onoda; Shuhei Yamaguchi; Ratko Radakovic
Journal:  Psychiatry Clin Neurosci       Date:  2020-05-07       Impact factor: 5.188

2.  Prospective observational cohort study of factors influencing trial participation in people with motor neuron disease (FIT-participation-MND): a protocol.

Authors:  Emily Beswick; Stella A Glasmacher; Rachel Dakin; Judith Newton; Alan Carson; Sharon Abrahams; Siddharthan Chandran; Suvankar Pal
Journal:  BMJ Open       Date:  2021-03-23       Impact factor: 2.692

3.  Clinical and cost-effectiveness of a New psychosocial intervention to support Independence in Dementia (NIDUS-family) for family carers and people living with dementia in their own homes: a randomised controlled trial.

Authors:  Alexandra Burton; Penny Rapaport; Marina Palomo; Kathryn Lord; Jessica Budgett; Julie Barber; Rachael Hunter; Laurie Butler; Jessica Vickerstaff; Kenneth Rockwood; Margaret Ogden; Debs Smith; Iain Lang; Gill Livingston; Briony Dow; Helen Kales; Jill Manthorpe; Kate Walters; Juanita Hoe; Vasiliki Orgeta; Quincy Samus; Claudia Cooper
Journal:  Trials       Date:  2021-12-02       Impact factor: 2.279

4.  Are there distinct dimensions of apathy? The argument for reappraisal.

Authors:  Shannon S Dickson; Masud Husain
Journal:  Cortex       Date:  2022-01-25       Impact factor: 4.644

5.  Person-centered assessment of apathy and resistance to care in people living with dementia: Review of existing measures.

Authors:  Benjamin T Mast; Emilee M Ertle; Ann Kolanowski; Gail Mountain; Esme Moniz-Cook; Margareta Halek
Journal:  Alzheimers Dement (N Y)       Date:  2022-07-26

6.  Bupropion for the Treatment of Apathy in Alzheimer Disease: A Randomized Clinical Trial.

Authors:  Franziska Maier; Annika Spottke; Jan-Philipp Bach; Claudia Bartels; Katharina Buerger; Richard Dodel; Andreas Fellgiebel; Klaus Fliessbach; Lutz Frölich; Lucrezia Hausner; Martin Hellmich; Stefan Klöppel; Arne Klostermann; Johannes Kornhuber; Christoph Laske; Oliver Peters; Josef Priller; Tanja Richter-Schmidinger; Anja Schneider; Kija Shah-Hosseini; Stefan Teipel; Christine A F von Arnim; Jens Wiltfang; Frank Jessen
Journal:  JAMA Netw Open       Date:  2020-05-01

7.  Clinical significance of self-descriptive apathy assessment in patients with neurological form of Wilson's disease.

Authors:  Marcin Leśniak; Magdalena Roessler-Górecka; Anna Członkowska; Joanna Seniów
Journal:  Neurol Sci       Date:  2021-06-14       Impact factor: 3.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.